Avastin vs Lucentis Letter sent to Vice-President Almunia on November 7th, 2013 Contact: Ilaria Passarani – [removed] Ref.: BEUC-X[removed] 2014 - Histoplasmosis - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-03-05 04:20:37 Health Genentech Macular degeneration Ranibizumab Novartis Hoffmann-La Roche Off-label use Presumed ocular histoplasmosis syndrome Medicine Pharmacology Bevacizumab		Avastin vs Lucentis Letter sent to Vice-President Almunia on November 7th, 2013 Contact: Ilaria Passarani – [removed] Ref.: BEUC-X[removed]/2014 Add to Reading List Source URL: www.beuc.org Download Document from Source Website File Size: 252,85 KB Share Document on Facebook

	A Avastin versus Lucentis: Why It Matters lthough Lucentis is a remarkably safe and effective treatment for exudative macular degeneration, it could cost our health care system over $9 billion, which DocID: 12Y6g - View Document
	Supplement to australian pharma JUNE 2013 DocID: 10GGY - View Document
	MD Research News Issue 200 Tuesday 30 September, 2014 This free weekly bulletin lists the latest published research articles on macular degeneration (MD) and some DocID: 10cRM - View Document
	Microsoft Word - Wet AMD_HS Panel_May 2010 _eng_ FINAL.doc DocID: Zk2W - View Document
	Supplement to australian pharma JUNE 2013 DocID: Ycn7 - View Document